Nutrients, Vol. 18, Pages 549: Hepatic UGT2B-Mediated Testosterone Clearance Promotes Lipid Accumulation in High-Fat-Diet-Induced MASLD
Nutrients doi: 10.3390/nu18030549
Authors:
Liping Zhou
Yingzhuan Zheng
Yujie Qiao
Xin Xu
Duoli Zhang
Yongqiong Shi
Yuanmeng Huang
Hongxiang Zeng
Ting Zeng
Xi Li
Linqiang Zhang
Background and Objective: Male individuals diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD) frequently present with decreased blood testosterone concentrations concomitant with increased levels of hepatic cholesterol, the fundamental substrate for testosterone synthesis; however, the mechanistic relationship between these phenomena remains inadequately elucidated. This study aimed to examine the involvement of hepatic cholesterol biosynthesis and testosterone metabolism in the pathogenesis of MASLD. Methods: An MASLD model was established in male C57BL/6J mice subjected to a high-fat diet (HFD). Comprehensive analyses, including hepatic transcriptomics, metabolomics, enzyme-linked immunosorbent assay, Western blotting, and quantitative polymerase chain reaction, were conducted. Additionally, in vitro experiments were performed using AML-12 hepatocytes treated with oleic acid and testosterone, with or without the presence of a uridine diphosphate-glucuronosyltransferase family 2 member B (UGT2B) enzyme inhibitor. Results: The HFD elevated cholesterol levels and activated cholesterol synthesis and testosterone metabolic pathways, notably characterized by upregulation of UGT2B enzymes and their transcriptional regulator, the aryl hydrocarbon receptor (AHR). Blood testosterone increased initially but decreased after 24 weeks of HFD. In vitro, testosterone alone did not affect oleic acid-induced lipid accumulation, but inhibiting UGT2B enabled testosterone levels to reduce lipid deposition and downregulate lipid uptake and synthesis pathways. Conclusions: The HFD induces dynamic, UGT2B-mediated hepatic testosterone metabolism. Compensatory early testosterone increase is offset by enhanced UGT2B-mediated clearance, resulting in eventual testosterone depletion and the loss of its protective effects against hepatic lipid accumulation. This explains the clinical paradox and suggests targeting the hepatic UGT2B enzymes as a potential MASLD treatment.
Background and Objective: Male individuals diagnosed with metabolic dysfunction-associated steatotic liver disease (MASLD) frequently present with decreased blood testosterone concentrations concomitant with increased levels of hepatic cholesterol, the fundamental substrate for testosterone synthesis; however, the mechanistic relationship between these phenomena remains inadequately elucidated. This study aimed to examine the involvement of hepatic cholesterol biosynthesis and testosterone metabolism in the pathogenesis of MASLD. Methods: An MASLD model was established in male C57BL/6J mice subjected to a high-fat diet (HFD). Comprehensive analyses, including hepatic transcriptomics, metabolomics, enzyme-linked immunosorbent assay, Western blotting, and quantitative polymerase chain reaction, were conducted. Additionally, in vitro experiments were performed using AML-12 hepatocytes treated with oleic acid and testosterone, with or without the presence of a uridine diphosphate-glucuronosyltransferase family 2 member B (UGT2B) enzyme inhibitor. Results: The HFD elevated cholesterol levels and activated cholesterol synthesis and testosterone metabolic pathways, notably characterized by upregulation of UGT2B enzymes and their transcriptional regulator, the aryl hydrocarbon receptor (AHR). Blood testosterone increased initially but decreased after 24 weeks of HFD. In vitro, testosterone alone did not affect oleic acid-induced lipid accumulation, but inhibiting UGT2B enabled testosterone levels to reduce lipid deposition and downregulate lipid uptake and synthesis pathways. Conclusions: The HFD induces dynamic, UGT2B-mediated hepatic testosterone metabolism. Compensatory early testosterone increase is offset by enhanced UGT2B-mediated clearance, resulting in eventual testosterone depletion and the loss of its protective effects against hepatic lipid accumulation. This explains the clinical paradox and suggests targeting the hepatic UGT2B enzymes as a potential MASLD treatment. Read More